A Case of Ischemic Heart Disease in Hormone Treatment with Castration Resistant Prostate Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Case of Ischemic Heart Disease in Hormone Treatment with Castration Resistant Prostate Cancer

Published:2015 Issue:10 Volume:41 Page:695-700
ISSN:1346-342X
Container-title:Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
language:en
Short-container-title:Jpn. J. Pharm. Health Care Sci.

Author:

Imakyure Osamu¹²,Sakata Yuri²,Otsuka Makoto²,Yamamoto Tomoka²,Yasutaka Yuki¹²,Washiyama Atsushi²,Gondo Masaki³,Nakamura Nobuyuki⁴,Futagami Koujiro¹²

Affiliation:

1. Department of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Science, Fukuoka University

2. Department of Hospital Pharmacy, Fukuoka University Hosipital

3. Cardiology, Fukuoka University Hosipital

4. Urology, Fukuoka University Hospital

Publisher

Japanese Society of Pharmaceutical Health Care and Sciences

Subject

General Earth and Planetary Sciences,General Environmental Science

Link

https://www.jstage.jst.go.jp/article/jjphcs/41/10/41_695/_pdf

Reference12 articles.

1. 1) de Voogt HJ, Smith PH, Pavone-Macaluso M, de Pauw M, Suciu S, Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762, J Urol, 1986, 135, 303-307.

2. 2) Lubiniecki GM, Berlin JA, Weinstein RB, Vaughn DJ, Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma, Cancer, 2004, 101, 2755-2759.

3. 3) Kuruma H, Fujita T, Shitara T, Egawa S, Yokohama E, Baba S, Weekly paclitaxel plus estramustine combination therapy in hormone-refractory prostate cancer: a pilot study, Int J Urol, 2003, 10, 470-475.

4. 4) Nakagami Y, Ohori M, Sakamoto N, Koga S, Hamada R, Hatano T, Tachibana M, Safety and efficacy of docetaxel, estramustine phosphate and hydrocortisone in hormone-refractory prostate cancer patients, Int J Urol, 2010, 17, 629-634.

5. 5) Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 2012, 367, 1187-1197.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3